Sells rapid diagnostic tests and sample-collection devices to healthcare and public-health organizations, consumers, and laboratories and researchers.
10-K for FY2025, filed Mar 9, 2026
Customers buy diagnostic tests and sample-collection products; they generally pay after shipment, though some pay before delivery. Other income comes from royalties linked to licensee sales and funding for research work, paid as activities are performed.
10-K for FY2025, filed Mar 9, 2026Product sales. Revenue from product sales is recognized upon transfer of control of a product to a customer based on an amount that…View ↗
Other revenues. Other revenues consist primarily of royalty income and funding from grants of research and development efforts. Royalties…View ↗
Financing and payment. The Company's payment terms vary by the type and location of the customer and products or services offered. Payment…View ↗
For certain products or services and customer types, the Company may require payment before the products are delivered or services are…View ↗
10-K for FY2025, filed Mar 9, 2026
FY2025 revenue by product or service ↗$115M
10-K for FY2025, filed Mar 9, 2026
$115M ↗| Segment | Share | Revenue | How money arrives |
|---|---|---|---|
|
Products and services
Sold outright
10-K for FY2025, filed Mar 9, 2026 |
95%
FY2022: 98%
|
Products and services, FY2025
$109.1M Sources
|
Sold outright |
|
Other
Mix
10-K for FY2025, filed Mar 9, 2026 |
5.2%
FY2022: 2.4%
|
Other, FY2025
$6M Sources
|
Mix |
Healthcare and public-health organizations and consumers buy diagnostic tests; laboratories, researchers and pharmaceutical companies buy sample-collection products. Sales use direct channels, strategic arrangements and independent distributors.
10-K for FY2025, filed Mar 9, 2026The Company's business consists of the development, manufacture, marketing, sale and distribution of simple, easy to use diagnostic…View ↗
The Company's business also includes sample management solutions and services that are used by clinical laboratories, direct-to-consumer…View ↗
The Company markets its products in the United States and internationally. It attempts to reach major target markets through a combination…View ↗
No. It lost $68.7M in FY2025.
10-Q for Q3 FY2026, filed Nov 9, 2026
−$13.1MView ↗
10-Q/A, filed Nov 12, 2026
Open tableView ↗
8-K, filed Nov 9, 2026
The Company is guiding to Q4 2026 total revenues of $30.0 million to $32.0 million. For the full year 2026, this represents a…View ↗
8-K, filed May 6, 2026
The Company is guiding to Q2 2026 Total revenues of $27 million to $30 million.View ↗
Shrinking. Revenue fell 51% in 4 years, from $233.7M in FY2021 to $115M in FY2025, about 16% a year.
Sickle-cell diagnostics
The older report described rapid HIV and hepatitis C tests; the newer report says the BioMedomics acquisition added SickleSCAN, a rapid sickle-cell disease test.
10-K for FY2022, filed Mar 3, 2023 10-K for FY2025, filed Mar 9, 2026Our Diagnostics business primarily consists of the development, manufacture, marketing and sale of simple, easy to use diagnostic products…View ↗
In November 2025, the Company acquired BioMedomics, Inc. (“BioMedomics”), pursuant to which BioMedomics became a wholly-owned subsidiary of…View ↗
Risk-assessment testing
The older report included drug-of-abuse tests processed in a laboratory; the newer report says the risk-assessment product line was discontinued.
10-K for FY2022, filed Mar 3, 2023Our Diagnostics business primarily consists of the development, manufacture, marketing and sale of simple, easy to use diagnostic products…View ↗
Laboratory services
The older report said Diversigen offered laboratory and analytical services for genomics and microbiome customers; the newer report says OraSure exited molecular services.
10-K for FY2022, filed Mar 3, 2023 10-K for FY2025, filed Mar 9, 2026Our Molecular Solutions products include the Colli-Pee® device, developed and sold by our Novosanis subsidiary, for the volumetric…View ↗
Molecular Services revenues, which were largely derived from the Company's microbiome molecular sequencing services, were nil for the year…View ↗
Loading...